GleamWall
中文EN

ENVB Enveric Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.78M$2.84M
SG&A expense$5.79M$6.45M
Operating income-$8.77M-$9.63M
Pretax income-$8.77M-$9.57M
Income tax—$8,930
Net income-$8.77M-$9.57M
EBITDA-$8.57M-$9.29M
EPS (basic)-36.24-228.48
EPS (diluted)-36.24-228.48
Weighted avg. shares (diluted)334,71941,908
Banking
Net interest income-$106$219
Balance sheet
Cash & equivalents$4.68M$2.24M
Current assets$4.94M$2.73M
PP&E, net$159,234$305,777
Intangibles—$42,182
Total assets$5.10M$3.08M
Current liabilities$918,400$1.49M
Total liabilities$918,400$1.49M
Shareholders' equity$4.18M$1.59M
Shares outstanding1.06M56,501
Cash flow statement
Operating cash flow-$8.14M-$7.73M
Financing cash flow$10.58M$7.67M
Depreciation & amortization$200,858$337,489
Stock-based compensation$827,323$1.56M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.